Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05250895 · ClinicalTrials.gov registry record · Early Phase 1
BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy
A Early Phase 1 study of Hepatocellular Carcinoma and BCLC Stage B Hepatocellular Carcinoma, sponsored by Emory University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT05250895 is a Early Phase 1 study of Hepatocellular Carcinoma and BCLC Stage B Hepatocellular Carcinoma that has completed, run by Emory University. The registered enrollment target is 9 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05250895, a Early Phase 1 study of Hepatocellular Carcinoma and BCLC Stage B Hepatocellular Carcinoma, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This early phase I trial evaluates the use of hypoxia (lack of oxygen) as a measure in determining the outcome of Y90 selective internal radiation therapy in patients with liver cancer that has spread to a limited number of sites (oligometastatic). Radioembolization with Y90 is a minimally invasive procedure that combines embolization and radiation therapy to treat metastatic liver cancer. Tiny beads filled with radioactive isotope Y-90 are placed inside the blood vessel that provide blood supply to the tumor. This will block the blood flow to the tumor cells while providing a high radiation dose without harming healthy normal tissue.
Conditions Studied
Interventions
- PROCEDURE Biopsy
- PROCEDURE Positron Emission Tomography
- PROCEDURE Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- OTHER 18F-Fluoromisonidazole
Study Locations (1)
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2022-04-28 |
| Est. Completion | 2025-02-26 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05250895
The ClinicalTrials.gov registry entry for NCT05250895 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (96% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Biopsy is the first listed.
NCT05250895 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT05250895 about?
NCT05250895 is a clinical study titled "BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy". This early phase I trial evaluates the use of hypoxia (lack of oxygen) as a measure in determining the outcome of Y90 selective internal radiation therapy in patients with liver cancer that has spread to a limited number of sites (oligometastatic). Radioembolization with Y90 is a minimally invasive ...
What is the current status of trial NCT05250895?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2022-04-28. Estimated completion is 2025-02-26.
What conditions does trial NCT05250895 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma.
What interventions are being tested in trial NCT05250895?
The interventions under investigation include: Biopsy (PROCEDURE), Positron Emission Tomography (PROCEDURE), Dynamic Contrast-Enhanced Magnetic Resonance Imaging (PROCEDURE), 18F-Fluoromisonidazole (OTHER).
Who is sponsoring clinical trial NCT05250895?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05250895 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SBRT + Atezolizumab + Bevacizumab in Resectable HCC
ACTIVE NOT RECRUITING · Early Phase 1
-
Molecular Basis of Pediatric Liver Cancer
RECRUITING
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.